Nanjing Hanxin Pharmaceutical Technology co.,Ltd.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the human GLP-1 hormone to regulate glucose levels, making it useful for treating type 2 diabetes and aiding in weight management 1. It is available as a once-weekly injection (Ozempic, Wegovy) or a daily oral tablet (Rybelsus), showing significant efficacy in lowering HbA1c and promoting weight loss 12. Common side effects are mostly gastrointestinal and typically lessen over time. Approved by the FDA for diabetes in 2017 and for weight management in 2021, semaglutide continues to be researched for its potential benefits in other areas 9.

This summary captures the essence of semaglutide's mechanism of action, its forms of administration, primary uses, notable efficacy outcomes, side effect profile, and regulatory milestones.